What is Vaginal Candidiasis Market?
Vaginal candidiasis is a fungal infection that causes irritation, discharge and intense itchiness of the vagina and the vulva, the tissues at the vaginal opening. It is commonly called a vaginal yeast infection. This infection affects up to 3 out of 4 women at some point in their lifetimes. It is estimated that 75% of women will have at least one yeast infection in her lifetime. The symptoms of vaginal candidiasis involve itchiness and discomfort.
The market study is being classified and major geographies with country level break-up.
Scynexis (United States), Synmedic Laboratories (India), Merck & Co., Inc. (United States), Astellas (Japan), Bayer AG (Germany), Mentis Pharma Ltd. (India), Abbott (United States), Novartis AG (Switzerland), Pfizer Inc. (United States) and Sanofi (France) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are ALLERGAN (Ireland) and AstraZeneca (United Kingdom).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Vaginal Candidiasis market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Vaginal Candidiasis market by Type, Application and Region.
On the basis of geography, the market of Vaginal Candidiasis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Number of Womens Affecting Vaginal Candidiasis
- Increased Awareness among People about Healthy Lifestyle
- RIse in the Number of Hospitals and Diagnostic Centres
- Roust Increase in the Distribution Channels
- Side Effects of the Medications used in Vaginal Candidiasis
- Increase in Research and Development Expenditure
- Strong Product Pipeline
- Growth in the Healthcare Industry
- Stringent Regulatory Conditions in Some Regions
Market Leaders and some development strategies
SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oral Ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. The submission is supported by positive results from two Phase 3, randomized, double-blind, placebo-controlled, multi-center studies (VANISH-303 and VANISH-306) in which oral Ibrexafungerp demonstrated statistical superiority over placebo with a favorable tolerability profile.
Key Target AudienceVaginal Candidiasis Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase